Context Therapeutics Inc. (CNTX)
(Delayed Data from NSDQ)
$2.48 USD
-0.02 (-0.80%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.48 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CNTX 2.48 -0.02(-0.80%)
Will CNTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTX
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
CNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Other News for CNTX
Buy Rating Affirmed for Context Therapeutics Amid Strong Financials and Promising CLDN6-Targeting Therapies
Context Therapeutics GAAP EPS of -$0.04
Buy Rating Affirmed for Context Therapeutics as CTIM-76 Shows Promise and Strategic Team Expands Ahead of Clinical Trials
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations